Riedl, M A <br/><br/>
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.  [electronic resource] 

 -  Allergy  Sep 2018 
 - 1871-1880 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1398-9995 
<br/><br/><label>Standard No.: </label>10.1111/all.13466  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Angioedemas, Hereditary--diagnosis<br/>Disease Progression<br/>Enzyme Inhibitors--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Plasma Kallikrein--antagonists & inhibitors<br/>Quality of Life<br/>Recurrence<br/>Treatment Outcome